ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.

Nicoletta  Colombo

Employment - Sarepta Therapeutics (I)

Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro

Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro

Robert L.  Coleman

Employment - US Oncology

Leadership - Onxeo

Stock and Other Ownership Interests  - McKesson

Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche; Genmab; Gradalis; Immunogen; Merck; Merck; Novocure; Oncolytics; OncoMed; OncXerna Therapeutics; Regeneron; Sotio; Tesaro

Research Funding - Abbott/AbbVie; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Immunogen (Inst); Johnson & Johnson; Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech

Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group

Xiaohua  Wu

No Relationships to Disclose

Fatih  Köse

Honoraria - Astellas Pharma (Inst); AstraZeneca (Inst); Deva (Inst); GlaxoSmithKline (Inst); Janssen (Inst); MSD/Merck (Inst); Nobelpharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Deva; GlaxoSmithKline; Janssen; MSD/Merck; Nobelpharma; Novartis; Pfizer; Roche; Takeda

Robert Michael  Wenham

Stock and Other Ownership Interests  - Ovation Diagnostics

Honoraria - Seagen; Tesaro

Consulting or Advisory Role - Abbvie; AstraZeneca; Clovis Oncology; Genentech; GlaxoSmithKline; Legend Biotech; Merck; Mersana; Regeneron; Seattle Genetics/Astellas; Tesaro

Speakers' Bureau - Clovis Oncology; Genentech; Tesaro

Research Funding - Anixa Biosciences (Inst); Merck (Inst); Prescient Therapeutics (Inst)

Travel, Accommodations, Expenses - TapImmune Inc.

Other Relationship - AstraZeneca; GlaxoSmithKline/Tesaro

Alexandra  Sebastianelli

Honoraria - AstraZeneca; GlaxoSmithKline; Merck

Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck

Kosei  Hasegawa

Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD K.K; Takeda

Consulting or Advisory Role - Kaken Pharmaceutical; MSD K.K

Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical

Emese  Zsiros

Honoraria - AstraZeneca; Survivornet; TeneoBio

Consulting or Advisory Role - Merck

Research Funding - Merck

Thibault  De La Motte Rouge

No Relationships to Disclose

Mariusz  Bidziński

No Relationships to Disclose

Iain A.  McNeish

Honoraria - AstraZeneca; Clovis Oncology

Consulting or Advisory Role - AstraZeneca; BeiGene; Carrick Therapeutics; Clovis Oncology; Epsila Bio; GlaxoSmithKline; Roche; Scancell Ltd.

Research Funding - AstraZeneca (Inst)

Travel, Accommodations, Expenses - AstraZeneca

Jalid  Sehouli

Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva

Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro

Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro

Jacob  Korach

Research Funding - Merck Sharp & Dohme (Inst)

Philip R.  Debruyne

Stock and Other Ownership Interests  - Alkermes; Biocartis

Honoraria - Bayer; Bristol-Myers Squibb; Merck/Pfizer; MSD; Roche

Research Funding - Pfizer (Inst)

Travel, Accommodations, Expenses - Janssen

Jae-Weon  Kim

No Relationships to Disclose

Andréia C.  de Melo

Honoraria - BMS Brazil; MSD Oncology; Novartis

Speakers' Bureau - BMS Brazil; MSD Oncology

Research Funding - AstraZeneca (Inst); BMS Brazil (Inst); Clovis Oncology (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)

Travel, Accommodations, Expenses - MSD Oncology

Xuan  Peng

Employment - Merck Sharp & Dohme

Agata M.  Bogusz

Employment - Merck Sharp & Dohme

Stock and Other Ownership Interests  - Merck

Karin Sayuri  Yamada

Employment - Merck Sharp & Dohme

Stock and Other Ownership Interests  - Merck

Bradley J.  Monk

Leadership - US Oncology

Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics

Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics

Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK

Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)